Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Rhea-AI Summary
Cytek Biosciences (Nasdaq: CTKB) will report fourth quarter and full year 2025 financial results after market close on Thursday, February 26, 2026.
Management will host a webcast and conference call beginning at 1:30 p.m. Pacific / 4:30 p.m. Eastern to discuss results, business developments, and outlook. Live audio will be available in the Investors section at investors.cytekbio.com.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CTKB declined 4.36%, reflecting a moderate negative market reaction. This price movement removed approximately $24M from the company's valuation, bringing the market cap to $533M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CTKB gained 1.16% while peers were mixed: LAB -3.6%, AVNS +2.93%, KIDS roughly flat, ZIMV flat. VREX appeared on the momentum scanner, up about 5.34%. The dispersion suggests this earnings-date announcement was primarily stock-specific rather than part of a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Prelim revenue update | Positive | +6.4% | Preliminary 2025 revenue with Q4 growth and segment strength highlighted. |
| Nov 12 | Growth recognition | Positive | +0.4% | TIME recognition as a growth leader emphasizing platform adoption and expansion. |
| Nov 06 | Product award | Positive | +1.8% | BioTech Breakthrough award for Cytek Muse Micro cell analyzer. |
| Nov 06 | Investor conferences | Neutral | +1.8% | Participation in multiple healthcare investor conferences and webcasts. |
| Nov 05 | Q3 2025 earnings | Neutral | +2.6% | Q3 2025 financial results with modest growth and reaffirmed 2025 revenue guidance. |
Recent news—including preliminary 2025 revenue and product/award recognitions—has generally been followed by positive share reactions, suggesting investors have rewarded operational updates and growth signals.
Over the past few months, Cytek has highlighted both financial and reputational milestones. On Nov 5, 2025, Q3 2025 results showed revenue of $52.3M with reaffirmed full‑year guidance, and the stock rose. November brought conference participation and a BioTech Breakthrough award for the Cytek Muse Micro analyzer, each accompanied by modest price gains. On Jan 12, 2026, preliminary 2025 revenue of about $201M and Q4 revenue of about $62M produced the strongest recent reaction. Today’s earnings date notice fits into this cadence of steadily building financial disclosure.
Market Pulse Summary
This announcement schedules the release of Cytek’s fourth quarter and full year 2025 results for February 26, 2026, with a webcast at 1:30 p.m. PT / 4:30 p.m. ET. It follows preliminary revenue figures and prior guidance updates disclosed in recent months. Investors may focus on how final audited numbers compare with those preliminaries, as well as any new outlook commentary, margin trends, and balance sheet details that build on the 2025 trajectory outlined in earlier filings.
AI-generated analysis. Not financial advice.
FREMONT, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 26, 2026. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
Live audio of the webcast will be available on the “Investors” section of the company website at investors.cytekbio.com
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com
FAQ
When will Cytek Biosciences (CTKB) release Q4 and full year 2025 results?
What time is the Cytek (CTKB) earnings webcast and conference call on February 26, 2026?
Where can investors access Cytek Biosciences (CTKB) live audio for the February 26, 2026 call?
Will Cytek management discuss outlook during the February 26, 2026 CTKB call?
How can shareholders listen to Cytek (CTKB) if they cannot attend the February 26, 2026 live webcast?
